Laboratorios Farmaceuticos RoviXMAD:ROVI +0.51%98 Operating Margin % is 7.93% as of Mar. 2026, which is 62% below its 10-year median of 20.98. GuruFocus rates XMAD:ROVI with a GF Score™ of 98/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 85.24% on this metric.
Laboratorios Farmaceuticos Rovi SA operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Operating Margin % or its related term are showing as below:
XMAD:ROVI'
s Operating Margin % Range Over the Past 10 Years
Min: 5.76 Med: 20.98 Max: 31.29
Current: 23.58
XMAD:ROVI's Operating Margin % is ranked better than 85.24% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs XMAD:ROVI: 23.58
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Laboratorios Farmaceuticos Rovi Operating Margin % Related Terms
Laboratorios Farmaceuticos Rovi Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ROVI vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Operating Margin % of 7.93% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 62% below median its historical median of 20.98. Over the past decade, Laboratorios Farmaceuticos Rovi's Operating Margin % has ranged from 5.76 to 31.29. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #141 out of 955 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Laboratorios Farmaceuticos Rovi's Operating Margin % too high?
Laboratorios Farmaceuticos Rovi's current Operating Margin % of 7.93% is 62% below median its 10-year median of 20.98. Over the past 10 years, this metric has ranged from a low of 5.76 to a high of 31.29. The Drug Manufacturers industry median Operating Margin % is 7.45. Laboratorios Farmaceuticos Rovi's value of 7.93% is 6.4% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #141 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 98/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #141 out of 955 companies for Operating Margin %. This places Laboratorios Farmaceuticos Rovi in the top 15% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.45. Laboratorios Farmaceuticos Rovi's value of 7.93% is 6.4% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Operating Margin % has ranged from 5.76 to 31.29 over the past decade. While the company's 10-year median is 20.98 vs. the industry median of 7.45, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Operating Margin % of 7.93% is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Operating Margin % is 7.93%, which is 62% below median its own 10-year median of 20.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €59.40 — trading 16.6% above its estimated fair value. The current Operating Margin % is 7.93%, which is 62% below median its 10-year median of 20.98 and 6.4% above the Drug Manufacturers industry median of 7.45. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Operating Margin % is 7.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €59.40 is trading 16.6% above its estimated GF Value™ of €50.93.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Operating Margin %: 7.93% (62% below median its 10-year median of 20.98)
GF Value™: €50.93 vs. price of €59.40 (16.6% above fair value)
Industry Position: 6.4% above the Drug Manufacturers median (#141 of 955)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
98GF Score
Get the complete analysis for XMAD:ROVI
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
